Clinical Trial Update: Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the efficacy, safety, and tolerability of NBI-1065890 versus placebo in adults with tardive dyskinesia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tardive Dyskinesia

Drugs mentioned

• NBI-1065890

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Tardive Dyskinesia | Phase 2 | Status: RECRUITING